Iroko's Zorvolex under FDA review for osteoarthritis pain
This article was originally published in Scrip
Executive Summary
The US FDA accepted for review Iroko Pharmaceuticals' supplemental new drug application (sNDA) for Zorvolex (diclofenac), a lower-dose nonsteroidal anti-inflammatory drug (NSAID), as a treatment for osteoarthritis pain in adults.